Which of the following problems is associated with intravenous augmentation of synthetic $\alpha$₁-antitrypsin for the patient with genetic emphysema?

Question

Quizplus · Accepted Answer

The primary issue with intravenous augmentation of synthetic alpha-1 antitrypsin (AAT) for treating genetic emphysema is the expense. This therapy is costly due to the complexity of producing the synthetic protein and the ongoing need for treatment.

Which of the Following Problems Is Associated with Intravenous Augmentation α\alphaα

Which of the Following Problems Is Associated with Intravenous Augmentation $\alpha$